Doxorubicin Market by Formulation, End-user, and Geography - Forecast and Analysis 2023-2027

Published: Mar 2023

Pages: 157

SKU: IRTNTR75032

Snapshot

The doxorubicin market is estimated to grow at a CAGR of 6.07% between 2022 and 2027. The size of the market is forecasted to increase by USD 469.97 million. The growth of the market depends on several factors, including the growing prevalence of cancer cases, increasing product launches, and advancements in diagnostic methods.

This report extensively covers market segmentation by formulation (lyophilized powder and doxorubicin injection), end-user (hospital pharmacy, retail pharmacy, online pharmacy, and others), and geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

What will be the Size of the Doxorubicin Market During the Forecast Period?

To learn more about this report, Download Report Sample

Doxorubicin Market: Key Drivers, Trends, Challenges, and Customer Landscape

The growing prevalence of cancer cases is notably driving the market growth, although factors such as late diagnosis and poor survival rates of patients with cancer may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Doxorubicin Market Driver

The growing prevalence of cancer cases is notably driving the doxorubicin market growth.
Some of the common types of cancers prevalent in the US are breast, cervical, and prostate cancers.
Risk factors such as diabetes, obesity, and related non-alcoholic fatty liver disease are associated with cancer.

Government organizations, research organizations, and pharmaceutical companies are investing high amounts in the R&D and treatment of cancer.
These factors will increase demand for doxorubicin drugs for cancer treatment, which, in turn, will drive the growth of the market during the forecast period.

Significant Doxorubicin Market Trend

The introduction of precision cancer medicine is a key trend influencing the doxorubicin market growth.
The development of novel technologies such as next-generation deoxyribonucleic acid (DNA) sequencing has led to a rapid increase in the understanding of genetic, molecular, and morphological changes in individual cancer patients.
This has led to the emergence of targeted therapies to treat cancer.
With the use of precision medicine, late-stage cancer can be treated.
The growing R&D in the oncology segment by vendors and contract research organizations (CROs) will lead to the launch of new precision cancer medicines.
These factors will support the growth of the market during the forecast period

Major Doxorubicin Market Challenge

Late diagnosis and poor survival rates of patients with cancer may impede the doxorubicin market growth.
According to the National Health Service (NHS), almost 50% of cancer patients in the UK are diagnosed at late stages, when it becomes difficult to control tumor growth.
The delay in diagnosis of cancer occurs at the patient, primary care, and secondary care levels.
During the late stages, the treatment of cancer using drug therapies becomes difficult, and surgery is often performed.
Hence, the late diagnosis and the poor survival rate associated with cancer limit the use of doxorubicin for the treatment of cancer and increase the mortality rates associated with cancer.

Key Doxorubicin Market Customer Landscape

The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Doxorubicin Market Customer Landscape

Who are the Major Doxorubicin Market Vendors?

Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Baxter International Inc. - The company offers doxorubicin such as Doxorubicin HCl liposome injection.

The report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

What are the Fastest-Growing Segments in the Doxorubicin Market?

The market share growth by the lyophilized powder segment will be significant during the forecast period. Lyophilization is a process wherein water is removed from a product after being frozen and placed under a vacuum, which allows ice to convert directly from solid to vapor without passing through a liquid phase. The advantages of lyophilization include product stability in a dry state, removal of water without excessive heating, and enhanced stability of a dry powder.

Get a glance at the market contribution of various segments Request a PDF Sample

The lyophilized powder segment was valued at USD 695.57 million in 2017 and continued to grow by 2021. Various vendors, such as Intas Pharmaceuticals, offer lyophilization powder for cancer treatment. Trastuzumab lyophilized powder by Intas Pharmaceuticals is used in treating metastatic breast cancer, early breast cancer, and metastatic gastric cancer. The growing number of breast cancer cases is one of the driving the demand for lyophilized powder. This, in turn, will drive the growth of the segment during the forecast period.

Which are the Key Regions for the Doxorubicin Market?

For more insights on the market share of various regions Request PDF Sample now!

North America is estimated to contribute 47% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

Cancer is one of the most common chronic diseases in North America. According to the Centers for Disease Control and Prevention (CDC), breast cancer is one of the most common types of cancer among women in the US. The region has been witnessing constant R&D activities in the oncology sector to lower the overall cancer mortality rate and help increase the life expectancy and quality of life of cancer patients. Awareness initiatives promoting are also contributing to the growth of the market in the region. Such factors will will drive the growth of the regional doxorubicin market during the forecast period.

This report forecasts the contribution of all the segments to the growth of the market. In addition, we have included the COVID-19 impact and the recovery strategies for each segment. The outbreak of COVID-19 negatively affected the growth of the doxorubicin market in 2020. Due to lockdown and travel restrictions, some private clinics were closed, which resulted in the decreased registration of cancer patients. However, in 2021, governments started vaccination programs and lifted lockdown and travel restrictions in this region. This, in turn, restored the demand for doxorubicin. Such factors will increase the demand for cancer treatment, which will drive the growth of the regional doxorubicin market during the forecast period.

Segment Overview

The report forecasts market growth by revenue at global, regional, and country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.

Formulation Outlook (USD Million, 2017 - 2027)
- Lyophilized powder
- Doxorubicin injection

End-user Outlook (USD Million, 2017 - 2027)
- Hospital pharmacy
- Retail pharmacy
- Online pharmacy
- Others

Region Outlook (USD Million, 2017 - 2027)
- North America
  - The U.S.
  - Canada
- Europe
  - The U.K.
  - Germany
  - France
  - Rest of Europe
- Asia
  - China
  - India
- ROW
  - Australia
  - Argentina
  - Rest of the world

Parent Market Analysis

The reports categorize the global doxorubicin market as a part of the pharmaceuticals market, which covers products and companies engaged in the R&D or production of generic drugs, non-generic drugs, and veterinary drugs. Technavio calculates the global healthcare market size based on the combined revenue generated by manufacturers/providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. Our research report has extensively covered external factors influencing the parent market growth during the forecast period.

Doxorubicin Market Scope
Report Coverage	Details
Page number	157
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 6.07%
Market growth 2023-2027	USD 469.97 million
Market structure	Fragmented
YoY growth 2022-2023(%)	5.45
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 47%
Key countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	Aurobindo Pharma Ltd., Baxter International Inc., Cipla Ltd., Dr Reddys Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals Plc, Intas Pharmaceuticals Ltd., Johnson and Johnson, Meiji Holdings Co. Ltd., Merck KGaA, Mitsui and Co. Ltd., Novartis AG, Pfizer Inc., Pharmagen CZ s.r.o, Sun Pharmaceutical Industries Ltd., Synbias Pharma AG, TTY Biopharm Co. Ltd., Zydus Lifesciences Ltd., S. G. Biopharm Pvt. Ltd., and Teva Pharmaceutical Industries Ltd.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Doxorubicin Market Report?

CAGR of the market during the forecast period
Detailed information on factors that will drive the growth of the doxorubicin market between 2023 and 2027
Precise estimation of the size of the doxorubicin market size and its contribution to the parent market
Accurate predictions about upcoming trends and changes in consumer behavior
Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
Thorough analysis of the market’s competitive landscape and detailed information about vendors
Comprehensive analysis of factors that will challenge the growth of doxorubicin market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

Table of Contents

1 Executive Summary

1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Formulation
- Exhibit 06: Executive Summary – Chart on Market Segmentation by End-user
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition

3.2 Market segment analysis
- Exhibit 13: Market segments

3.3 Market size 2022

3.4 Market outlook: Forecast for 2022-2027
- Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

4.1 Global doxorubicin market 2017 - 2021
- Exhibit 18: Historic Market Size – Data Table on Global doxorubicin market 2017 - 2021 ($ million)

4.2 Formulation Segment Analysis 2017 - 2021
- Exhibit 19: Historic Market Size – Formulation Segment 2017 - 2021 ($ million)

4.3 End-user Segment Analysis 2017 - 2021
- Exhibit 20: Historic Market Size – End-user Segment 2017 - 2021 ($ million)

4.4 Geography Segment Analysis 2017 - 2021
- Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)

4.5 Country Segment Analysis 2017 - 2021
- Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Formulation

6.1 Market segments
- Exhibit 30: Chart on Formulation - Market share 2022-2027 (%)
- Exhibit 31: Data Table on Formulation - Market share 2022-2027 (%)

6.2 Comparison by Formulation
- Exhibit 32: Chart on Comparison by Formulation
- Exhibit 33: Data Table on Comparison by Formulation

6.3 Lyophilized powder - Market size and forecast 2022-2027
- Exhibit 34: Chart on Lyophilized powder - Market size and forecast 2022-2027 ($ million)
- Exhibit 35: Data Table on Lyophilized powder - Market size and forecast 2022-2027 ($ million)
- Exhibit 36: Chart on Lyophilized powder - Year-over-year growth 2022-2027 (%)
- Exhibit 37: Data Table on Lyophilized powder - Year-over-year growth 2022-2027 (%)

6.4 Doxorubicin injection - Market size and forecast 2022-2027
- Exhibit 38: Chart on Doxorubicin injection - Market size and forecast 2022-2027 ($ million)
- Exhibit 39: Data Table on Doxorubicin injection - Market size and forecast 2022-2027 ($ million)
- Exhibit 40: Chart on Doxorubicin injection - Year-over-year growth 2022-2027 (%)
- Exhibit 41: Data Table on Doxorubicin injection - Year-over-year growth 2022-2027 (%)

6.5 Market opportunity by Formulation
- Exhibit 42: Market opportunity by Formulation ($ million)
- Exhibit 43: Data Table on Market opportunity by Formulation ($ million)

7 Market Segmentation by End-user

7.1 Market segments
- Exhibit 44: Chart on End-user - Market share 2022-2027 (%)
- Exhibit 45: Data Table on End-user - Market share 2022-2027 (%)

7.2 Comparison by End-user
- Exhibit 46: Chart on Comparison by End-user
- Exhibit 47: Data Table on Comparison by End-user

7.3 Hospital pharmacy - Market size and forecast 2022-2027
- Exhibit 48: Chart on Hospital pharmacy - Market size and forecast 2022-2027 ($ million)
- Exhibit 49: Data Table on Hospital pharmacy - Market size and forecast 2022-2027 ($ million)
- Exhibit 50: Chart on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
- Exhibit 51: Data Table on Hospital pharmacy - Year-over-year growth 2022-2027 (%)

7.4 Retail pharmacy - Market size and forecast 2022-2027
- Exhibit 52: Chart on Retail pharmacy - Market size and forecast 2022-2027 ($ million)
- Exhibit 53: Data Table on Retail pharmacy - Market size and forecast 2022-2027 ($ million)
- Exhibit 54: Chart on Retail pharmacy - Year-over-year growth 2022-2027 (%)
- Exhibit 55: Data Table on Retail pharmacy - Year-over-year growth 2022-2027 (%)

7.5 Online pharmacy - Market size and forecast 2022-2027
- Exhibit 56: Chart on Online pharmacy - Market size and forecast 2022-2027 ($ million)
- Exhibit 57: Data Table on Online pharmacy - Market size and forecast 2022-2027 ($ million)
- Exhibit 58: Chart on Online pharmacy - Year-over-year growth 2022-2027 (%)
- Exhibit 59: Data Table on Online pharmacy - Year-over-year growth 2022-2027 (%)

7.6 Others - Market size and forecast 2022-2027
- Exhibit 60: Chart on Others - Market size and forecast 2022-2027 ($ million)
- Exhibit 61: Data Table on Others - Market size and forecast 2022-2027 ($ million)
- Exhibit 62: Chart on Others - Year-over-year growth 2022-2027 (%)
- Exhibit 63: Data Table on Others - Year-over-year growth 2022-2027 (%)

7.7 Market opportunity by End-user
- Exhibit 64: Market opportunity by End-user ($ million)
- Exhibit 65: Data Table on Market opportunity by End-user ($ million)

8 Customer Landscape

8.1 Customer landscape overview
- Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
- Exhibit 67: Chart on Market share by geography 2022-2027 (%)
- Exhibit 68: Data Table on Market share by geography 2022-2027 (%)

9.2 Geographic comparison
- Exhibit 69: Chart on Geographic comparison
- Exhibit 70: Data Table on Geographic comparison

9.3 North America - Market size and forecast 2022-2027
- Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%)
- Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%)

9.4 Europe - Market size and forecast 2022-2027
- Exhibit 75: Chart on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 76: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 77: Chart on Europe - Year-over-year growth 2022-2027 (%)
- Exhibit 78: Data Table on Europe - Year-over-year growth 2022-2027 (%)

9.5 Asia - Market size and forecast 2022-2027
- Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%)
- Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%)

9.6 Rest of World (ROW) - Market size and forecast 2022-2027
- Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

9.7 US - Market size and forecast 2022-2027
- Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%)
- Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%)

9.8 Germany - Market size and forecast 2022-2027
- Exhibit 91: Chart on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 92: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 93: Chart on Germany - Year-over-year growth 2022-2027 (%)
- Exhibit 94: Data Table on Germany - Year-over-year growth 2022-2027 (%)

9.9 China - Market size and forecast 2022-2027
- Exhibit 95: Chart on China - Market size and forecast 2022-2027 ($ million)
- Exhibit 96: Data Table on China - Market size and forecast 2022-2027 ($ million)
- Exhibit 97: Chart on China - Year-over-year growth 2022-2027 (%)
- Exhibit 98: Data Table on China - Year-over-year growth 2022-2027 (%)

9.10 UK - Market size and forecast 2022-2027
- Exhibit 99: Chart on UK - Market size and forecast 2022-2027 ($ million)
- Exhibit 100: Data Table on UK - Market size and forecast 2022-2027 ($ million)
- Exhibit 101: Chart on UK - Year-over-year growth 2022-2027 (%)
- Exhibit 102: Data Table on UK - Year-over-year growth 2022-2027 (%)

9.11 Canada - Market size and forecast 2022-2027
- Exhibit 103: Chart on Canada - Market size and forecast 2022-2027 ($ million)
- Exhibit 104: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
- Exhibit 105: Chart on Canada - Year-over-year growth 2022-2027 (%)
- Exhibit 106: Data Table on Canada - Year-over-year growth 2022-2027 (%)

9.12 Market opportunity by geography
- Exhibit 107: Market opportunity by geography ($ million)
- Exhibit 108: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers

10.2 Market challenges

10.3 Impact of drivers and challenges
- Exhibit 109: Impact of drivers and challenges in 2022 and 2027

10.4 Market trends

11 Vendor Landscape

11.1 Overview

11.2 Vendor landscape
- Exhibit 110: Overview on Criticality of inputs and Factors of differentiation

11.3 Landscape disruption
- Exhibit 111: Overview on factors of disruption

11.4 Industry risks
- Exhibit 112: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
- Exhibit 113: Vendors covered

12.2 Market positioning of vendors
- Exhibit 114: Matrix on vendor position and classification

12.3 Baxter International Inc.
- Exhibit 115: Baxter International Inc. - Overview
- Exhibit 116: Baxter International Inc. - Business segments
- Exhibit 117: Baxter International Inc. - Key news
- Exhibit 118: Baxter International Inc. - Key offerings
- Exhibit 119: Baxter International Inc. - Segment focus

12.4 Cipla Ltd.
- Exhibit 120: Cipla Ltd. - Overview
- Exhibit 121: Cipla Ltd. - Business segments
- Exhibit 122: Cipla Ltd. - Key news
- Exhibit 123: Cipla Ltd. - Key offerings
- Exhibit 124: Cipla Ltd. - Segment focus

12.5 Dr Reddys Laboratories Ltd.
- Exhibit 125: Dr Reddys Laboratories Ltd. - Overview
- Exhibit 126: Dr Reddys Laboratories Ltd. - Business segments
- Exhibit 127: Dr Reddys Laboratories Ltd. - Key offerings
- Exhibit 128: Dr Reddys Laboratories Ltd. - Segment focus

12.6 Hikma Pharmaceuticals Plc
- Exhibit 129: Hikma Pharmaceuticals Plc - Overview
- Exhibit 130: Hikma Pharmaceuticals Plc - Business segments
- Exhibit 131: Hikma Pharmaceuticals Plc - Key offerings
- Exhibit 132: Hikma Pharmaceuticals Plc - Segment focus

12.7 Intas Pharmaceuticals Ltd.
- Exhibit 133: Intas Pharmaceuticals Ltd. - Overview
- Exhibit 134: Intas Pharmaceuticals Ltd. - Product / Service
- Exhibit 135: Intas Pharmaceuticals Ltd. - Key offerings

12.8 Johnson and Johnson
- Exhibit 136: Johnson and Johnson - Overview
- Exhibit 137: Johnson and Johnson - Business segments
- Exhibit 138: Johnson and Johnson - Key news
- Exhibit 139: Johnson and Johnson - Key offerings
- Exhibit 140: Johnson and Johnson - Segment focus

12.9 Meiji Holdings Co. Ltd.
- Exhibit 141: Meiji Holdings Co. Ltd. - Overview
- Exhibit 142: Meiji Holdings Co. Ltd. - Business segments
- Exhibit 143: Meiji Holdings Co. Ltd. - Key news
- Exhibit 144: Meiji Holdings Co. Ltd. - Key offerings
- Exhibit 145: Meiji Holdings Co. Ltd. - Segment focus

12.10 Merck KGaA
- Exhibit 146: Merck KGaA - Overview
- Exhibit 147: Merck KGaA - Business segments
- Exhibit 148: Merck KGaA - Key news
- Exhibit 149: Merck KGaA - Key offerings
- Exhibit 150: Merck KGaA - Segment focus

12.11 Novartis AG
- Exhibit 151: Novartis AG - Overview
- Exhibit 152: Novartis AG - Business segments
- Exhibit 153: Novartis AG - Key offerings
- Exhibit 154: Novartis AG - Segment focus

12.12 Pfizer Inc.
- Exhibit 155: Pfizer Inc. - Overview
- Exhibit 156: Pfizer Inc. - Product / Service
- Exhibit 157: Pfizer Inc. - Key news
- Exhibit 158: Pfizer Inc. - Key offerings

12.13 S. G. Biopharm Pvt. Ltd.
- Exhibit 159: S. G. Biopharm Pvt. Ltd. - Overview
- Exhibit 160: S. G. Biopharm Pvt. Ltd. - Product / Service
- Exhibit 161: S. G. Biopharm Pvt. Ltd. - Key offerings

12.14 Sun Pharmaceutical Industries Ltd.
- Exhibit 162: Sun Pharmaceutical Industries Ltd. - Overview
- Exhibit 163: Sun Pharmaceutical Industries Ltd. - Product / Service
- Exhibit 164: Sun Pharmaceutical Industries Ltd. - Key offerings

12.15 Synbias Pharma AG
- Exhibit 165: Synbias Pharma AG - Overview
- Exhibit 166: Synbias Pharma AG - Product / Service
- Exhibit 167: Synbias Pharma AG - Key offerings

12.16 Teva Pharmaceutical Industries Ltd.
- Exhibit 168: Teva Pharmaceutical Industries Ltd. - Overview
- Exhibit 169: Teva Pharmaceutical Industries Ltd. - Business segments
- Exhibit 170: Teva Pharmaceutical Industries Ltd. - Key news
- Exhibit 171: Teva Pharmaceutical Industries Ltd. - Key offerings
- Exhibit 172: Teva Pharmaceutical Industries Ltd. - Segment focus

12.17 Zydus Lifesciences Ltd.
- Exhibit 173: Zydus Lifesciences Ltd. - Overview
- Exhibit 174: Zydus Lifesciences Ltd. - Business segments
- Exhibit 175: Zydus Lifesciences Ltd. - Key offerings
- Exhibit 176: Zydus Lifesciences Ltd. - Segment focus

13 Appendix

13.1 Scope of the report

13.2 Inclusions and exclusions checklist
- Exhibit 177: Inclusions checklist
- Exhibit 178: Exclusions checklist

13.3 Currency conversion rates for US$
- Exhibit 179: Currency conversion rates for US$

13.4 Research methodology
- Exhibit 180: Research methodology
- Exhibit 181: Validation techniques employed for market sizing
- Exhibit 182: Information sources

13.5 List of abbreviations
- Exhibit 183: List of abbreviations

Methodology

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

Manufacturers and suppliers
Channel partners
Industry experts
Strategic decision makers

Secondary sources

Industry journals and periodicals
Government data
Financial reports of key industry players
Historical data
Press releases

DATA ANALYSIS

Data Synthesis

Collation of data
Estimation of key figures
Analysis of derived insights

Data Validation

Triangulation with data models
Reference against proprietary databases
Corroboration with industry experts

REPORT WRITING

Qualitative

Market drivers
Market challenges
Market trends
Five forces analysis

Quantitative

Market size and forecast
Market segmentation
Geographical insights
Competitive landscape

Purchase Report

PURCHASE FULL REPORT OF

doxorubicin market

Buy Report - Single User License 2500 USD

QUICK BUY

Key Questions Answered

What are the key global market and the regional market share?
What are the revenue-generating key market segments?
What are the key factors driving and challenging this market’s growth?
Who are the key market vendors and their growth strategies?
What are the latest trends influencing the growth of this market?
What are the variables influencing the market growth in the primary regions?
What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

Off-the-shelf research reports
Reports can be tailored to meet the customer's needs
Trusted by more than 100 fortune 500 organizations
Information about the market's key drivers, trends, and challenges
Parent market analysis
Every week, 50,000 people visit our subscription platform
Detailed vendors report with competitive landscape
Covid-19 impact and recovery analysis
Data on revenue-generating market segments
Details on the market shares of various regions
Five-force market analysis